Abstract: Neuroleptically active octahydro-1H-pyrrolo[2,3-g]isoquinolines of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and X are as hereinafter set forth, are described.
Abstract: This invention provides a novel class of 2-iminoimidazolidines which include 4-substituted derivatives such as 4-(2-chloroethyl)-1-methyl-2-methylimino-3-phenyl imidazolidine fumarate: ##STR1## This illustrated 4-substituted 2-iminoimidazolidine compound exhibits cardiovascular hypotensive, hypoglycemic (glucose tolerance, and sugar cataract) and anti-inflammatory (pleural effusion) pharmacological activities in test animals.
Abstract: Isoquinoline derivatives of the formula: ##STR1## wherein R.sub.1 represents alkyl of 1 through 8 carbon atoms, and n represents 1 or 2, are new compounds possessing useful pharmacological properties. They are particularly valuable as analgesic, anti-inflammatory, antipyretic or antiviral agents.
Type:
Grant
Filed:
May 6, 1980
Date of Patent:
September 1, 1981
Assignee:
Rhone-Poulenc Industries
Inventors:
Daniel Farge, Alain Jossin, Gerard Ponsinet, Daniel Reisdorf
Abstract: A method for preparing 1,2,3,4-tetrahydroisoquinolines comprising heating N-halo or hydroxyethyl-N-benzylamines in an aluminum chloride melt at 160.degree.-210.degree..
Type:
Grant
Filed:
August 10, 1978
Date of Patent:
February 17, 1981
Assignee:
SmithKline Corporation
Inventors:
Bing L. Lam, Wilford L. Mendelson, Charles B. Spainhour, Jr.
Abstract: 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof having the formula ##STR1## and the non-toxic pharmacologically acceptable acid addition salts thereof; wherein R is hydrogen, benzyl, or an alkyl radical of 1 to 7 carbon atoms; R.sup.1 is hydrogen or an alkyl radical of 1 to 7 carbon atoms; R.sup.2 in each occurrence is hydrogen, an alkyl radical of 1 to 7 carbon atoms or alkoxy radical of 1 to 7 carbon atoms, alike or different; Ar is phenyl optionally substituted with one or more halogen, an alkyl radical of 1 to 7 carbon atoms, or alkoxy radical of 1 to 7 carbon atoms; and n is positive integer less than 4, are disclosed. These compounds are useful because of their anti-arrhythmic, antimicrobial and central nervous system activity.
Abstract: 1,2,3,4-tetrahydroisoquinolines have the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each hydrogen, lower alkyl, lower alkenyl, acyl, aryl or ar(lower)alkyl, in which aryl and the aryl moiety of the ar(lower)alkyl may contain at least one substituent selected from the group consisting of halogen, lower alkoxy, amino, nitro, hydroxy, acyloxy, ar(lower)alkoxy, lower alkylenedioxy, halo(lower)alkyl, acylamino, ar(lower)alkylamino and aryl, and pharmaceutically acceptable salts thereof.
Abstract: Heterocyclic compounds characterized by the formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, X and z are as hereinafter set forth,prepared, inter alia, by reacting a compound characterized by the formula ##STR2## with an amine characterized by the formula ##STR3## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, X and Y are as hereinafter set forth,are described. The end products are useful as fungicidal agents.
Abstract: A novel process for preparing 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline by cyclizing N-acetyl-2,3-dichlorobenzylaminoacetaldehyde dimethyl acetal with a Lewis acid, reducing, and hydrolyzing the resulting acylated isoquinoline is disclosed.